A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

NCT00240695 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

724

Enrollment

INDUSTRY

Sponsor class

Conditions

Cognition Disorder
Nervous System Diseases
Mental Disorders
Brain Diseases

Interventions

DRUG: galantamine hydrobromide

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.